A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

BACKGROUND: Robatumumab (19D12; MK‐7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin‐like growth factor receptor‐1 (IGF‐1R). This multiinstitutional study (P04720) determined the safety and clinical efficacy of robatumumab in three separate patient group...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Peter M., Bielack, Stefan S., Gorlick, Richard G., Skubitz, Keith, Daw, Najat C., Herzog, Cynthia E., Monge, Odd R., Lassaletta, Alvaro, Boldrini, Erica, Pápai, Zsuzanna, Rubino, Joseph, Pathiraja, Kumudu, Hille, Darcy A., Ayers, Mark, Yao, Siu‐Long, Nebozhyn, Michael, Lu, Brian, Mauro, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129487/
https://www.ncbi.nlm.nih.gov/pubmed/27362300
http://dx.doi.org/10.1002/pbc.26087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129487/
https://www.ncbi.nlm.nih.gov/pubmed/27362300
http://dx.doi.org/10.1002/pbc.26087

Ejemplares similares